Investigating JAK inhibition for skin diseases in individuals with Down syndrome
Use of specific JAK inhibition on inflammatory skin and scalp diseases in Down syndrome
This study is looking at how a new type of medicine called JAK inhibitors can help people with Down syndrome who have skin issues like eczema and hair loss, aiming to find a safer and more effective treatment than what’s usually available.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11131253 on NIH RePORTER |
What this research studies
This research focuses on the use of JAK inhibitors to treat inflammatory skin conditions commonly seen in individuals with Down syndrome, such as atopic dermatitis and alopecia areata. The study aims to explore how these medications can reduce inflammation caused by the overactive JAK/STAT signaling pathway, which is prevalent in this population. By utilizing a targeted approach, the research seeks to provide a safer and more effective treatment option compared to traditional immunosuppressive therapies, which often come with significant side effects. Patients will be monitored for safety and efficacy throughout the treatment period.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with Down syndrome who are experiencing inflammatory skin conditions.
Not a fit: Patients without Down syndrome or those not suffering from inflammatory skin diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved management of inflammatory skin diseases in individuals with Down syndrome, enhancing their quality of life.
How similar studies have performed: Previous studies have shown promising results with JAK inhibitors in treating similar inflammatory conditions, indicating a potential for success in this novel application.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Guttman, Emma — Icahn School of Medicine at Mount Sinai
- Study coordinator: Guttman, Emma
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.